RecruitingPhase 2NCT06112704

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

A Phase 2, Open-label, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (ARTEMIS-005)

Sponsor

Hansoh BioMedical R&D Company

Enrollment

220 participants

Start Date

Feb 6, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests HS-20093, a new antibody-drug conjugate (a targeted therapy that delivers chemotherapy directly to cancer cells), in patients with advanced esophageal cancer or other solid tumors that have not responded to prior treatments. **You may be eligible if...** - You are 18 or older with confirmed advanced, relapsed, or metastatic esophageal cancer or another solid tumor - You have at least one measurable area of disease on scans - Your general performance status is good (ECOG 0–1) - Your estimated survival is more than 12 weeks - You are willing to use adequate contraception **You may NOT be eligible if...** - You have had prior treatment with B7-H3-targeted therapy - You have had recent chemotherapy, major surgery, or radiation within 2–4 weeks before starting the study - You have evidence of active bleeding, severe infection, or uncontrolled systemic disease - You have active hepatitis B or C - You are pregnant or breastfeeding - You have a history of severe allergic reactions to antibody-drug treatments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHS-20093

Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Locations(21)

Anhui Provincial Cancer Hospital

Hefei, Anhui, China

Fujian Provincial Tumor Hospital

Fujian, Fujian, China

The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army

Fuzhou, Fujian, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Tumour Hospital of Anyang city

Anyang, Henan, China

The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Henan, China

Nanyang Central Hospital

Nanyang, Henan, China

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Nantong Tumor Hospital

Nantong, Jiangsu, China

Jiangyin People's Hospital

Wuxi, Jiangsu, China

Jiangxi Provincial Tumor Hospital

Nanchang, Jiangxi, China

Liaoning Cancer Hospital

Shenyang, Liaoning, China

The First Hospital of China Medical University

Shenyang, Liaoning, China

Affiliated Hospital of Jining Medical University

Jining, Shandong, China

Sichuan Cancer Hospital&Institude, Sichuan Cancer Center,Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China

Chengdu, Sichuan, China

The Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06112704

Related Trials

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT0664190811 locations

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT0598170327 locations

SW-682 in Advanced Solid Tumors

NCT062513108 locations

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT0683300813 locations

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

NCT051033454 locations